Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug

Purpose of review The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations. Although TDF is well tolerated, the potential for kidney and bone toxicity has important implications for public health given the large number of individuals exposed to TDF worldwide. This review summarizes the recent literature on kidney and bone health in individuals treated with TDF and the newer prodrug tenofovir alafenamide (TAF). Recent findings Risk factors for TDF toxicity appear to be similar in patients treated for HIV or hepatitis B virus and in HIV-uninfected PrEP users, although drug–drug interactions are a more important concern in HIV-positive individuals. The risk of toxicity appears to be lower with TAF, but further studies are needed to confirm the safety of long-term use and to evaluate the efficacy of TAF-based PrEP. Summary Nephrologists should be aware of the potential kidney and bone toxicity of TDF, as well as unique situations in which the newer prodrug TAF may contribute to kidney injury.

[1]  J. Baeten,et al.  Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis , 2017, Journal of acquired immune deficiency syndromes.

[2]  E. Vittinghoff,et al.  Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project , 2017, Journal of acquired immune deficiency syndromes.

[3]  E. Clementi,et al.  Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF , 2017, Journal of acquired immune deficiency syndromes.

[4]  M. Wainberg,et al.  Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. , 2017, The lancet. HIV.

[5]  D. Fine,et al.  Tenofovir alafenamide nephrotoxicity in an HIV-positive patient , 2017, Medicine.

[6]  C. Leen,et al.  Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  S. Oka,et al.  Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1–Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort , 2017, AIDS patient care and STDs.

[8]  S. Antinori,et al.  Renal function in HIV/HBV co‐infected and HBV mono‐infected patients on a long‐term treatment with tenofovir in real life setting , 2017, Clinical and experimental pharmacology & physiology.

[9]  C. Gordon,et al.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  B. Clotet,et al.  Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity , 2016, BioMed research international.

[11]  K. Suresh,et al.  Tenofovir-induced nephrotoxicity: A retrospective cohort study. , 2016, The Medical journal of Malaysia.

[12]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[13]  J. Baeten,et al.  Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. , 2016, Journal of Infectious Diseases.

[14]  M. Buti,et al.  Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study , 2016, Journal of clinical gastroenterology.

[15]  F. Palella,et al.  Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men , 2016, Journal of acquired immune deficiency syndromes.

[16]  B. Mâsse,et al.  PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials , 2016, Journal of acquired immune deficiency syndromes.

[17]  B. Kearney,et al.  Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment , 2016, Antimicrobial Agents and Chemotherapy.

[18]  K. Tashima,et al.  Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results , 2016, Journal of acquired immune deficiency syndromes.

[19]  J. Baeten,et al.  Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. , 2016, Journal of acquired immune deficiency syndromes.

[20]  J. Baeten,et al.  Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis , 2016, Journal of acquired immune deficiency syndromes.

[21]  K. Lichtenstein,et al.  Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study , 2016, Journal of acquired immune deficiency syndromes.

[22]  Abdur Rahman Khan,et al.  Fanconi Syndrome and Antiretrovirals: It Is Never Too Late , 2016, American journal of therapeutics.

[23]  J. Baeten,et al.  Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention , 2016, Expert opinion on drug safety.

[24]  F. Liaño,et al.  Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir , 2016, AIDS.

[25]  F. Palella,et al.  HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  J. van Lunzen,et al.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. , 2016, The Lancet. Infectious diseases.

[27]  C. B. Hare,et al.  No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Podzamczer,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials , 2015, The Lancet.

[29]  Jimena García,et al.  Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients , 2015, International Journal of Clinical Pharmacy.

[30]  D. Glidden,et al.  Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  A. Mocroft,et al.  Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study , 2015, PLoS medicine.

[32]  J. Baeten,et al.  Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. , 2015, JAMA internal medicine.

[33]  T. Santantonio,et al.  Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. , 2014, The Journal of antimicrobial chemotherapy.

[34]  M. Buti,et al.  Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection , 2014, Digestive Diseases and Sciences.

[35]  P. Lampertico,et al.  Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[36]  P. Sax,et al.  Changes in Proteinuria and Albuminuria With Initiation of Antiretroviral Therapy: Data From a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine Versus Abacavir/Lamivudine , 2014, Journal of acquired immune deficiency syndromes.

[37]  M. Shlipak,et al.  A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans , 2014, AIDS.

[38]  R. Ebrahimi,et al.  Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients , 2014, PloS one.

[39]  A. Kosaka,et al.  Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat , 2014, Kidney international.

[40]  D. Glidden,et al.  Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis , 2014, AIDS.

[41]  P. Snelling,et al.  Tenofovir-Associated Fanconi Syndrome in Patients with Chronic Hepatitis B Monoinfection , 2013, Antiviral therapy.

[42]  U. Bredeek,et al.  Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults , 2013, Journal of acquired immune deficiency syndromes.

[43]  C. Hendrix,et al.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial , 2013, The Lancet.

[44]  K. Squires,et al.  Bone Health and Human Immunodeficiency Virus Infection , 2013, Pharmacotherapy.

[45]  P. Pang,et al.  Randomized, placebo‐controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B , 2012, Hepatology.

[46]  M. Shlipak,et al.  Association of tenofovir exposure with kidney disease risk in HIV infection , 2012, AIDS.

[47]  J. Stockman,et al.  Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men , 2012 .

[48]  B. Hendry,et al.  Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[49]  S. Hosseini,et al.  Tenofovir Renal Proximal Tubular Toxicity Is Regulated By OAT1 and MRP4 Transporters , 2011, Laboratory Investigation.

[50]  V. D’Agati,et al.  Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. , 2010, Kidney international.

[51]  U. Walker,et al.  Mitochondrial Tubulopathy in Tenofovir Disoproxil Fumarate-Treated Rats , 2009, Journal of acquired immune deficiency syndromes.

[52]  V. Soriano,et al.  Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[54]  B. Gazzard,et al.  The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years , 2007, AIDS.

[55]  G. Braden,et al.  Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.